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It is often presumed that cancers found to be late-stage at diagnosis
are due to late-stage at presentation by the patient or diagnostic
delay. Rapid tumour growth is an alternative explanation but it is
difficult to measure the rate of growth of tumours. Gross volume
doubling time estimates can only be made accurately in some situ-
ations, such as using serial chest radiographic measurements, and
this is only possible if the patient is not receiving anti-cancer treat-
ment. Tumour volume doubling time is a balance between tumour
growth and cell loss due to apoptosis, necrosis and sloughing.
There is no accurate way of measuring cell loss factor. However, it
is possible to measure the cell birth rate in vivo by labelling
tumours with DNA precursor bromodeoxyuridine (BrdUrd).
Flowcytometry is used to measure the proliferative parameters
BrdUrd labelling index (LI) DNA synthesis time (Ts) and potential
doubling time (Tpot). Tpot is defined as the time in which the cell
population would double if there was no cell loss. Previously we
have shown that labelling index measured during this non-toxic
assay has been shown to be an independent prognostic variable in
a multi-variate analysis and a predictor of local control following
radical radiotherapy (Bolger et al, 1996). Other investigators have
reported similar observations (Tsang et al, 1999).
In this study we have tried to answer whether diagnostic delay
or rapid tumour proliferation is responsible for late-stage cervical
cancer.
MATERIALS AND METHODS
Over a 20-month period all patients in the west of Scotland with
cervical cancer referred for either radiotherapy (Beatson Oncology
Centre, n = 141) or radical surgery (Stobhill Hospital or Glasgow
Royal Infirmary, n = 36) were interviewed before treatment. The
duration of symptoms (irregular vaginal bleeding, discharge or
pain) and date of last normal cervical smear were recorded.
Socioeconomic status was derived from the residential postal code
(Carstairs and Morris, 1991). The tumour stage was assessed
according to FIGO criteria during an examination under anaes-
thetic. Written informed consent was obtained from 146 patients
for administration of 200 mg of bromodeoxyuridine (BrdUrd) 6–8
h before the staging EUA (approved by Ethics Committee). A
mean of 2.8 biopsies (range 1–6) were obtained from each tumour
and fixed in 70% ethanol. A 50 mg portion of each biopsy was
disaggregated by pepsin to produce a nuclear suspension and the
incorporated BrdUrd was revealed by partial denaturation of the
DNA by hydrochloric acid. The BrdUrd was detected using a
mouse anti-BrdUrd monoclonal antibody (Dako) and a FITC
conjugated goat anti-mouse antibody (Sigma Chemicals). The
DNA was fluorescently stained with propidium iodide and
samples were analysed on a Coulter Epics Profile II flow
cytometer for S-phase duration (Ts). BrdUrd labelling index (LI)
and tumour potential doubling time (Tpot) were calculated (Bolger
et al, 1993). Both rate of growth parameters were skewed, with
longer tails to the right. A logarithmic transformation brought each
distribution sufficiently close to normality and an analysis of vari-
ance was undertaken to test for a linear trend across the four
stages.
RESULTS
Prior to diagnosis, 53% (95) of patients had never had a cervical
smear. Such patients tended to be older (mean age 63.3 years).
Only 27.6% (49) had a smear taken within the previous 5 years.
However, it is noteworthy that the diagnosis of asymptomatic
invasive cancer was made following a routine smear in 13 patients
(5.7%) (Table 1). We could find no association with deprivation
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significant difference in the stage distribution exists when
comparing symptomatic and asymptomatic cases (P = 0.03, Table
3). However, amongst the symptomatic cases 94/131 (72%) were
late-stage and this group showed no evidence of a trend between
stage and duration of symptoms (P = 0.54).
There was a trend suggesting women in higher deprivation cate-
gories had a long duration of symptoms but this was not statisti-
cally significant (Table 4). There was no correlation between stage
at diagnosis and deprivation (P = 0.34).
Crude and adjusted labelling index (LI corrected for ploidy) was
calculated either as the average LI from multiple biopsies or as a
maximum value from one biopsy. The average LI may be less than
the maximum recorded result owing to normal cell contamination
and necrotic or slowly dividing tumour cells in the biopsies
assayed. The maximum labelling index is representative of the
most rapidly dividing part of the tumour which is probably the
tissue most likely to decide the ultimate clinical outcome. There is
a statistically significant trend for patients with increasing tumour
stage to have higher mean LI measurements both for average
values (P = 0.035), and for maximum measurements (P = 0.001,
Figure 1). The mean potential doubling times show the same trend
with the mean Tpot decreasing with increasing stage. This rela-
tionship is not significant for average values (P = 0.10) but is
significant when maximum values only are considered (P = 0.023,
Figure 1). The stronger relationship with stage is observed with LI,
and when both LI and Tpot are included in a multivariate model
only LI is independently associated with stage.
Data looking at the role of socioeconomic deprivation is contra-
dictory. The Tpot values for socioeconomically deprived patients
are significantly shorter than those for affluent patients when
average Tpot values from all biopsies are considered (P = 0.04),
but the relationship was far from significant for maximum values.
DISCUSSION
We know of no other studies comparing tumour stage, diagnostic
delay and a reliable measurement of tumour proliferation. Our
study was carried out during a time-period when a considerable
effort was made in the west of Scotland to improve screening for
cervical cancer. If the asymptomatic cases detected by screening
are excluded, there is no relationship between duration of symp-
toms and the stage of detection. However, we do observe a statisti-
cally significant trend for advanced tumours to have higher
labelling indices. There is also a trend for advanced tumours to
have shorter potential doubling times if maximum LI measure-
ments are used to calculate Tpot. This suggests that advanced-
stage tumours have more rapid proliferation rates, shorter potential
doubling times and by inference more rapid growth. Tumour stage
at diagnosis seems more influenced by the biology of the cancer
rather than diagnostic delay.
Duration of vaginal bleeding has been shown to be associated
with tumour stage in endometrial cancer (Obermair et al, 1996).
However, no association was found between delay and tumour
stage at diagnosis in Belgian patients suffering from squamous
cancer of the head and neck (Dhooge et al, 1996), a group of
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Table 1 Cervical smear history
Last smear Number of Mean age
women (years)
No previous smear 95 63.3
> 5 years ago 33 51.7
3–5 years ago 29 46.1
<3 years ago 20 41.2
Table 2 Deprivation category in relation to compliance to cervical screening
programme. Information only available for 163 patients, no postal code for
four patients, deprivation category not determined for 10 patients (sparsely
populated areas)
Smear history Deprivation category
Affluent Average Deprived
≤ 5 years (n = 43) 29.7% 31.3% 19.4%
> 5 years (n = 120) 70.3% 68.7% 80.6%
χ 2 = 2.6, P = 0.28
Table 3 Duration of symptoms in relation to tumour stage
Duration of
symptoms Stage Total
Early (I or IIa) Late (≥ IIb)
(n = 45) (n = 99)
No symptoms 17.8% (8) 5.1% (5) 13
≤ 3 months 37.8% (17) 50.5% (50) 67
3–12 months 28.9% (13) 28.3% (28) 41
> 1 year 15.5% (7) 16.1% (16) 23
All cases symptomatic vs asymptomatic χ 2 = 4.65, P = 0.03; Symptomatic
cases only test for trend χ 2 = 0.38, P = 0.54
Table 4 Duration of symptoms in relation to deprivation category
Duration of
symptoms Deprivation category
Affluent Average Deprived
(n = 37) (n = 64) (n = 62)
No symptoms 16.2% (6) 18.7% (12) 22.5% (14)
≤ 3 months 56.8% (21) 34.4% (22) 38.7% (24)
3–12 months 27.0% (10) 29.7% (19) 19.4% (12)
> 1 year 0 17.2% (11) 19.4% (12)
χ 2 = 11.8, P = 0.066
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Figure 1 Relationship between stage, maximum adjusted labelling index
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tumours with some biological features in common with cervical
cancer including a rapid potential doubling time (Wilson et al,
1995). The incidence of cervical cancer in the most socioeconomi-
cally deprived is three times more common than in the most
affluent in the west of Scotland. Moreover, the more deprived are
more likely to die, as the cancer tends to be more advanced at diag-
nosis (Lamont et al, 1993). Poor survival of cervical cancer
patients in New York City also seemed to be associated with low
income (Serur et al, 1995).
Our data suggests that two factors may account for the poor
prognosis of deprived patients. There is a non-significant trend for
more deprived patients to have a greater duration of symptoms.
However, proliferation rates may be more rapid in less affluent
women, but this observation requires further confirmation in a
larger group of patients.
The increased incidence and possibly a more malignant pheno-
type in the less affluent may be accounted for by lifestyle factors
including smoking and diet. Low serum vitamin A has been shown
to be a risk-factor in the development of cervical cancer (Eckhert
et al, 1995). Interestingly, smoking has been associated with low
levels of plasma beta-carotene. An additional finding was that, in
contrast to non-smokers, dietary beta-carotene supplements failed
to increase plasma levels in smokers (Palan et al, 1998). There is a
very strong association between human papilloma virus infection
and cervical cancer (Lombard et al, 1998). Retinoids are important
regulators of human papilloma virus and can inhibit growth of
cervical carcinoma cells in culture by transcription repression
(Bartsch et al, 1992).
Recently the Office of National Statistics has shown (Coleman
et al, 1999) that in England and Wales the affluent had a better
survival after cancer treatment in 44 out of 47 cancers studies.
Clearly this effect may be multifactorial, including possible better
access to medical care by the affluent, but lifestyle factors shaping
the tumour phenotype may also be important.
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